\u0130leri D\u00fczey Akci\u011fer Kanserinde TIL Tedavisine Direncin Nedenleri \u00dczerine Yeni Bulgular<\/p>\n
\u0130mm\u00fcnoterapi, \u00f6zellikle t\u00fcm\u00f6r infiltrasyonlu lenfosit (TIL) tedavisi, kanserle m\u00fccadelede \u00f6nemli bir umut olarak \u00f6n plana \u00e7\u0131kmaktad\u0131r. Akci\u011fer kanserinde ise bu tedavi y\u00f6ntemi, baz\u0131 hastalarda etkili sonu\u00e7lar verirken, baz\u0131 hastalarda yeterli cevap al\u0131namamaktad\u0131r. Moffitt Kanser Merkezi taraf\u0131ndan Nature Cancer dergisinde yay\u0131mlanan yeni bir \u00e7al\u0131\u015fma, \u00f6zellikle metastatik non-small cell lung cancer (NSCLC) hastalar\u0131nda TIL tedavisine diren\u00e7 g\u00f6steren vakalarda ya\u015fanan temel zorluklar\u0131 ortaya koymaktad\u0131r. Bu \u00f6nemli ara\u015ft\u0131rma, tedavinin etkinli\u011fini engelleyen molek\u00fcler ve h\u00fccresel mekanizmalar\u0131 detayl\u0131 olarak a\u00e7\u0131klayarak, tedavi stratejilerinde yeni y\u00f6nelimlere kap\u0131 aralamaktad\u0131r.<\/p>\n
TIL tedavisi, kanser hastalar\u0131n\u0131n kendi ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden \u00e7\u0131kar\u0131lan lenfositlerin, t\u00fcm\u00f6r dokusundan al\u0131narak laboratuvar ortam\u0131nda \u00e7o\u011falt\u0131lmas\u0131 ve hastaya tekrar verilmesi esas\u0131na dayanan yenilik\u00e7i bir yakla\u015f\u0131md\u0131r. Bu y\u00f6ntemde, t\u00fcm\u00f6r i\u00e7indeki ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccreleri se\u00e7ilir, \u00e7o\u011falt\u0131l\u0131r ve tekrar v\u00fccuda verilir. B\u00f6ylece t\u00fcm\u00f6re kar\u015f\u0131 daha yo\u011fun ve etkili bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015fturulmas\u0131 hedeflenir. Yayg\u0131n olarak melanom gibi baz\u0131 kanser t\u00fcrlerinde ba\u015far\u0131s\u0131 kan\u0131tlanm\u0131\u015f olan TIL tedavisi, NSCLC\u2019de ise kal\u0131c\u0131 ve yayg\u0131n kullan\u0131m sa\u011flayacak d\u00fczeyde etkili sonu\u00e7lar vermekte zorluk ya\u015famaktad\u0131r.<\/p>\n
Moffitt ekibinin \u00e7al\u0131\u015fmas\u0131nda NSCLC hastalar\u0131ndan al\u0131nan \u00f6rnekler, TIL tedavisine yan\u0131t veren ve vermeyen hastalar aras\u0131nda kar\u015f\u0131la\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r. Sonu\u00e7lar, tedaviye cevap vermeyen hastalarda en b\u00fcy\u00fck sorunun, inf\u00fcze edilen (verilen) TIL h\u00fccrelerinin v\u00fccutta uzun s\u00fcre hayatta kalmamas\u0131 ve fonksiyonel olarak aktif kalamamas\u0131 oldu\u011funu g\u00f6stermi\u015ftir. Bu durum, anti-t\u00fcm\u00f6r ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n zamanla azalmas\u0131na ve t\u00fcm\u00f6r\u00fcn tekrar b\u00fcy\u00fcmesine olanak sa\u011flamaktad\u0131r. Uzun s\u00fcre etkili TIL h\u00fccrelerinin varl\u0131\u011f\u0131 ise tedavi ba\u015far\u0131s\u0131nda kritik rol oynamaktad\u0131r.<\/p>\n
\u00c7al\u0131\u015fmada ortaya \u00e7\u0131kan bir di\u011fer \u00f6nemli fakt\u00f6r ise t\u00fcm\u00f6r antijenlerinde, \u00f6zellikle neoantijenlerde tedavi boyunca ya\u015fanan kay\u0131plard\u0131r. Neoantijenler, t\u00fcm\u00f6r h\u00fccrelerinde olu\u015fan mutasyonlarla ortaya \u00e7\u0131kan ba\u011f\u0131\u015f\u0131kl\u0131k sistemi i\u00e7in \u00f6zg\u00fcn i\u015faret\u00e7iler olup, TIL h\u00fccrelerinin kanseri tan\u0131mas\u0131nda b\u00fcy\u00fck rol oynar. Diren\u00e7 g\u00f6steren hastalarda neoantijenlerin azalmas\u0131 veya tamamen kaybolmas\u0131, t\u00fcm\u00f6r\u00fcn ba\u011f\u0131\u015f\u0131kl\u0131k g\u00f6z\u00fcnden kaybolmas\u0131na ve savunma mekanizmalar\u0131n\u0131n g\u00fc\u00e7lenmesine yol a\u00e7m\u0131\u015ft\u0131r. Bu durum, t\u00fcm\u00f6r\u00fcn ba\u011f\u0131\u015f\u0131kl\u0131k bask\u0131s\u0131ndan uzakla\u015farak ilerlemesini kolayla\u015ft\u0131ran kritik bir adaptasyon olarak g\u00f6r\u00fclmektedir.<\/p>\n
Ara\u015ft\u0131rman\u0131n \u00f6nemli ortak yazarlar\u0131ndan Dr. Chao Wang, bu direncin \u00e7ok fakt\u00f6rl\u00fc oldu\u011funu vurgulayarak, hem TIL h\u00fccrelerinin s\u00fcrd\u00fcr\u00fclebilirli\u011fi hem de neoantijenlerin korunmas\u0131n\u0131n tedavi ba\u015far\u0131s\u0131 i\u00e7in \u015fart oldu\u011funu belirtmi\u015ftir. Bu iki zorluk, TIL tedavisi alan hastalarda dayan\u0131kl\u0131 ve s\u00fcrekli bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015fturman\u0131n \u00f6n\u00fcndeki en b\u00fcy\u00fck engellerdir. Dolay\u0131s\u0131yla, ilerleyen d\u00f6nemde bu mekanizmalar hedef al\u0131narak daha etkili tedavi y\u00f6ntemleri geli\u015ftirilmesi gerekti\u011fi \u00f6ne \u00e7\u0131kmaktad\u0131r.<\/p>\n
T\u00fcm\u00f6r i\u00e7indeki TIL h\u00fccre havuzu ba\u015far\u0131l\u0131 tedavi g\u00f6ren hastalarda yeterli say\u0131da ve fonksiyonel aktivitede devam ederken, diren\u00e7 g\u00f6steren hastalarda T h\u00fccreleri h\u0131zl\u0131 bir \u015fekilde etkinli\u011fini yitirmi\u015f, hastal\u0131k ilerlemesiyle paralel bir azalma g\u00f6zlemlenmi\u015ftir. Buna ek olarak, t\u00fcm\u00f6r\u00fcn ba\u011f\u0131\u015f\u0131kl\u0131k sistemi taraf\u0131ndan tan\u0131nabilir neoantijenlerdeki zamanla ya\u015fanan kay\u0131plar, T cell i\u015flev kayb\u0131n\u0131 derinle\u015ftirmi\u015ftir. Bu durum, t\u00fcm\u00f6r\u00fcn ba\u011f\u0131\u015f\u0131kl\u0131k bask\u0131s\u0131na kar\u015f\u0131 evrimle\u015fmesi ve adaptif ka\u00e7\u0131\u015f mekanizmalar\u0131n\u0131n geli\u015fmesi ile a\u00e7\u0131klanabilir.<\/p>\n
Moffitt Kanser Merkezi\u2019nde g\u00f6revli Dr. Ben Creelan, bu bulgular \u0131\u015f\u0131\u011f\u0131nda yeni tedavi stratejilerinin gereklili\u011fine dikkat \u00e7ekmektedir. \u00d6zellikle, inf\u00fcze edilen TIL h\u00fccrelerinin canl\u0131l\u0131k s\u00fcresinin art\u0131r\u0131lmas\u0131 ve fonksiyonlar\u0131n\u0131n optimize edilmesi gereken birincil alan olarak \u00f6ne \u00e7\u0131kmaktad\u0131r. Ayr\u0131ca, t\u00fcm\u00f6r antijenlerinin stabilizasyonu ya da kaybedilen neoantijenlerin tekrar kazand\u0131r\u0131lmas\u0131 i\u00e7in molek\u00fcler ve genetik m\u00fcdahalelerin terap\u00f6tik etkileri ara\u015ft\u0131r\u0131lmal\u0131d\u0131r. Gen d\u00fczenleme teknolojileri ile olu\u015fturulacak daha dayan\u0131kl\u0131 ve fonksiyonel TIL h\u00fccreleri, ba\u011f\u0131\u015f\u0131kl\u0131k evazyonunu \u00f6nlemede anahtar olabilir.<\/p>\n
T\u00fcm\u00f6r\u00fcn antijenik profilinin y\u00f6netimini sa\u011flamak, a\u00e7\u0131\u011fa \u00e7\u0131kan \u00f6nemli bir di\u011fer geli\u015fme alan\u0131d\u0131r. Neoantijen kayb\u0131n\u0131n \u00f6n\u00fcne ge\u00e7ebilmek, kaybolan antijenlerin yeniden ifade edilmesi ya da molek\u00fcler taklit yap\u0131lmas\u0131, t\u00fcm\u00f6r\u00fcn ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden ka\u00e7mas\u0131na engel olabilir. B\u00f6ylece TIL h\u00fccreleri, s\u00fcrekli ve tan\u0131yabilir hedeflerle olan temas\u0131n\u0131 s\u00fcrd\u00fcrerek etkili kanser h\u00fccresi \u00f6ld\u00fcrme kapasitesini devam ettirebilir.<\/p>\n
Ara\u015ft\u0131rma ekibi, hastalardan elde ettikleri dizilim ve analiz verilerini Ulusal Sa\u011fl\u0131k Enstit\u00fcleri (NIH) ar\u015fivlerinde kamuya a\u00e7m\u0131\u015ft\u0131r. Bu hamle, global bilim d\u00fcnyas\u0131nda i\u015f birli\u011fini art\u0131rmay\u0131 ve farkl\u0131 ara\u015ft\u0131r\u0131c\u0131lar\u0131n direnci a\u015fmaya y\u00f6nelik kombinasyon tedavileri geli\u015ftirmesini te\u015fvik etmeyi ama\u00e7lamaktad\u0131r. Payla\u015f\u0131lan verilerin geni\u015f \u00e7apl\u0131 kullan\u0131m\u0131, ba\u011f\u0131\u015f\u0131kl\u0131k terapileri alan\u0131nda yeni ke\u015fiflerin h\u0131zlanmas\u0131n\u0131 sa\u011flayacakt\u0131r.<\/p>\n
Bu \u00e7al\u0131\u015fma, ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerinin kal\u0131c\u0131l\u0131\u011f\u0131 ile t\u00fcm\u00f6r\u00fcn immunolojik adaptasyon stratejileri aras\u0131nda dinamik bir etkile\u015fim oldu\u011funu ortaya koymaktad\u0131r. Bu nedenle ba\u011f\u0131\u015f\u0131kl\u0131k terapilerinin tasar\u0131m\u0131, sadece TIL h\u00fccrelerinin hayatta kalmas\u0131na ve kal\u0131c\u0131 fonksiyonel aktivite g\u00f6stermesine odaklanmak yerine, t\u00fcm\u00f6r mikro\u00e7evresinin mod\u00fclasyonu ve antijen ifadesinin korunmas\u0131n\u0131 da kapsamal\u0131d\u0131r. B\u00f6yle bir b\u00fct\u00fcnc\u00fcl yakla\u015f\u0131mla, klinik ara\u015ft\u0131rmalar daha etkili kombinasyon tedavileri sunabilecek \u015fekilde kurgulanabilir.<\/p>\n
TIL tedavisindeki ilerlemeler, y\u00fcksek \u00e7\u00f6z\u00fcn\u00fcrl\u00fckl\u00fc dizileme, tek h\u00fccre profillemesi ve gen m\u00fchendisli\u011fi teknolojileri gibi modern ara\u00e7larla desteklenmektedir. Bu \u00e7ok boyutlu strateji, ki\u015fiye \u00f6zel imm\u00fcnoterapi olanaklar\u0131n\u0131 geli\u015ftirmekte; hastalar\u0131n t\u00fcm\u00f6r yap\u0131s\u0131na ve ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin dinamiklerine g\u00f6re en uygun tedavi plan\u0131n\u0131n olu\u015fturulmas\u0131n\u0131 m\u00fcmk\u00fcn k\u0131lmaktad\u0131r. B\u00f6ylelikle NSCLC hastalar\u0131nda tedavi ba\u015far\u0131s\u0131 art\u0131r\u0131labilir.<\/p>\n
Uzun vadede, TIL h\u00fccrelerinin ya\u015famas\u0131 ve fonksiyonunu kaybetmemesi ile t\u00fcm\u00f6r\u00fcn immunolojik olarak g\u00f6r\u00fcn\u00fcr kalmas\u0131, bu tedavi y\u00f6nteminin deneysel bir se\u00e7enek olmaktan \u00e7\u0131k\u0131p rutin ve birinci basamak bir terapi haline gelmesini sa\u011flayacakt\u0131r. Moffitt Kanser Merkezi\u2019nin \u00f6nc\u00fcl\u00fc\u011f\u00fcnde s\u00fcrd\u00fcr\u00fclen bu ara\u015ft\u0131rma, ileri evre akci\u011fer kanserinde ya\u015fam s\u00fcresi ve ya\u015fam kalitesini belirgin \u015fekilde art\u0131racak tedavilerin geli\u015ftirilmesinde kritik bir kilometre ta\u015f\u0131d\u0131r.<\/p>\n
Ortaya konan biyolojik mekanizmalar ve onlar\u0131n klinik yans\u0131malar\u0131, ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin kanserle m\u00fccadelesinde kar\u015f\u0131la\u015f\u0131lan zorluklar\u0131n daha iyi anla\u015f\u0131lmas\u0131n\u0131 sa\u011flamakta, dolay\u0131s\u0131yla yeni nesil TIL tedavilerinin tasarlanmalar\u0131na y\u00f6nelik bilimsel altyap\u0131y\u0131 g\u00fc\u00e7lendirmektedir. Kanser tedavisinde ba\u011f\u0131\u015f\u0131kl\u0131k modifikasyonunun gelece\u011fi, bu tip b\u00fct\u00fcnc\u00fcl ve \u00e7ok disiplinli ara\u015ft\u0131rmalarla \u015fekillenmeye devam edecektir.<\/p>\n
Moffitt Kanser Merkezi, ba\u011f\u0131\u015f\u0131kl\u0131k direncine dair biyolojik temelleri a\u00e7\u0131\u011fa \u00e7\u0131karma konusunda \u00f6nc\u00fc rol oynamakta ve bu do\u011frultuda yeni tedavi yakla\u015f\u0131mlar\u0131 geli\u015ftirmeye devam etmektedir. Bu kapsamda, imm\u00fcnoterapide kar\u015f\u0131la\u015f\u0131lan diren\u00e7 mekanizmalar\u0131n\u0131 hedef alan \u00e7al\u0131\u015fmalar, ileri evre akci\u011fer kanseri ile m\u00fccadelede s\u00fcrd\u00fcr\u00fclebilir remisyon ve hastalar\u0131n ya\u015fam kalitesinde belirgin iyile\u015fmeler sa\u011flamay\u0131 ama\u00e7lamaktad\u0131r.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: \u0130nsan (Kanser Hastalar\u0131)<\/p>\n Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy<\/p>\n Haberin Yay\u0131n Tarihi<\/strong>: 8-May-2025<\/p>\n Web References<\/strong>: Doi Referans<\/strong>: http:\/\/dx.doi.org\/10.1038\/s43018-025-00946-x<\/p>\n Anahtar Kelimeler<\/strong>: \u0130mm\u00fcnoterapi, T\u00fcm\u00f6r \u0130nfiltrasyonlu Lenfositler, Akci\u011fer Kanseri, Non-Small Cell Lung Cancer, T H\u00fccresi Kal\u0131c\u0131l\u0131\u011f\u0131, Neoantijen Kayb\u0131, T\u00fcm\u00f6r Ba\u011f\u0131\u015f\u0131kl\u0131k Ka\u00e7\u0131\u015f\u0131, H\u00fccresel \u0130mm\u00fcnoterapi, Kanser Diren\u00e7 Mekanizmalar\u0131<\/p>\n","protected":false},"excerpt":{"rendered":" \u0130leri D\u00fczey Akci\u011fer Kanserinde TIL Tedavisine Direncin Nedenleri \u00dczerine Yeni Bulgular \u0130mm\u00fcnoterapi, \u00f6zellikle t\u00fcm\u00f6r infiltrasyonlu lenfosit (TIL) tedavisi, kanserle m\u00fccadelede \u00f6nemli bir umut olarak \u00f6n plana \u00e7\u0131kmaktad\u0131r. Akci\u011fer kanserinde ise bu tedavi y\u00f6ntemi, baz\u0131 hastalarda etkili sonu\u00e7lar verirken, baz\u0131 hastalarda yeterli cevap al\u0131namamaktad\u0131r. Moffitt Kanser Merkezi taraf\u0131ndan Nature Cancer dergisinde yay\u0131mlanan yeni bir \u00e7al\u0131\u015fma, \u00f6zellikle…<\/p>\n","protected":false},"author":1,"featured_media":5194,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[6379,6378,6380,6377,6376],"tmauthors":[],"class_list":{"0":"post-5193","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-akciger-kanserinde-til-hucrelerinin-hayatta-kalmasi","9":"tag-kanser-neoantijen-kaybi-ve-immunoterapi-direnci","10":"tag-metastatik-non-small-cell-lung-cancer-immunoterapisi","11":"tag-nsclc-hastalarinda-til-tedavisi-etkinligi","12":"tag-tumor-infiltrasyonlu-lenfosit-tedavisinde-direnc-mekanizmalari"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/05\/Tumor-Antijen-Reaktivitesinin-TIL-Tedavisindeki-Rolu-1746716454.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=5193"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5193\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/5194"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=5193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=5193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=5193"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=5193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nMoffitt Kanser Merkezi: https:\/\/moffitt.org\/
\nTIL Terapisi Hakk\u0131nda Bilgi: https:\/\/www.moffitt.org\/treatments\/immunotherapy\/til-therapy\/<\/p>\n